Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.
(2015) In Neurobiology of Disease 82. p.430-444- Abstract
- The neuroprotective properties of cystamine identified in pre-clinical studies have fast-tracked this compound to clinical trials in Huntington's disease, showing tolerability and benefits on motor symptoms. We tested whether cystamine could have such properties in a Parkinson's disease murine model and now provide evidence that it can not only prevent the neurodegenerative process but also can reverse motor impairments created by a 6-hydroxydopamine lesion 3weeks post-surgery. Importantly, we report that cystamine has neurorestorative properties 5weeks post-lesion as seen on the number of nigral dopaminergic neurons which is comparable with treatments of cysteamine, the reduced form of cystamine used in the clinic, as well as rasagiline,... (More)
- The neuroprotective properties of cystamine identified in pre-clinical studies have fast-tracked this compound to clinical trials in Huntington's disease, showing tolerability and benefits on motor symptoms. We tested whether cystamine could have such properties in a Parkinson's disease murine model and now provide evidence that it can not only prevent the neurodegenerative process but also can reverse motor impairments created by a 6-hydroxydopamine lesion 3weeks post-surgery. Importantly, we report that cystamine has neurorestorative properties 5weeks post-lesion as seen on the number of nigral dopaminergic neurons which is comparable with treatments of cysteamine, the reduced form of cystamine used in the clinic, as well as rasagiline, increasingly prescribed in early parkinsonism. All three compounds induced neurite arborization of the remaining dopaminergic cells which was further confirmed in ex vivo dopaminergic explants derived from Pitx3-GFP mice. The disease-modifying effects displayed by cystamine/cysteamine would encourage clinical testing. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7845059
- author
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Neurobiology of Disease
- volume
- 82
- pages
- 430 - 444
- publisher
- Elsevier
- external identifiers
-
- pmid:26232588
- wos:000364980000041
- scopus:84939627579
- pmid:26232588
- ISSN
- 0969-9961
- DOI
- 10.1016/j.nbd.2015.07.012
- language
- English
- LU publication?
- yes
- id
- 4a66a39f-93ee-4156-9e5f-f6625eca888a (old id 7845059)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26232588?dopt=Abstract
- date added to LUP
- 2016-04-01 10:41:54
- date last changed
- 2022-02-17 20:27:22
@article{4a66a39f-93ee-4156-9e5f-f6625eca888a,
abstract = {{The neuroprotective properties of cystamine identified in pre-clinical studies have fast-tracked this compound to clinical trials in Huntington's disease, showing tolerability and benefits on motor symptoms. We tested whether cystamine could have such properties in a Parkinson's disease murine model and now provide evidence that it can not only prevent the neurodegenerative process but also can reverse motor impairments created by a 6-hydroxydopamine lesion 3weeks post-surgery. Importantly, we report that cystamine has neurorestorative properties 5weeks post-lesion as seen on the number of nigral dopaminergic neurons which is comparable with treatments of cysteamine, the reduced form of cystamine used in the clinic, as well as rasagiline, increasingly prescribed in early parkinsonism. All three compounds induced neurite arborization of the remaining dopaminergic cells which was further confirmed in ex vivo dopaminergic explants derived from Pitx3-GFP mice. The disease-modifying effects displayed by cystamine/cysteamine would encourage clinical testing.}},
author = {{Cisbani, G and Drouin-Ouellet, Janelle and Gibrat, C and Saint-Pierre, M and Lagacé, M and Badrinarayanan, S and Lavallée-Bourget, M H and Charest, J and Chabrat, A and Boivin, L and Lebel, M and Bousquet, M and Lévesque, M and Cicchetti, F}},
issn = {{0969-9961}},
language = {{eng}},
pages = {{430--444}},
publisher = {{Elsevier}},
series = {{Neurobiology of Disease}},
title = {{Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.}},
url = {{https://lup.lub.lu.se/search/files/2063432/8838739.pdf}},
doi = {{10.1016/j.nbd.2015.07.012}},
volume = {{82}},
year = {{2015}},
}